Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases

Abstract

BACKGROUND & AIMS: We aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy. METHODS: We obtained biopsies from inflamed colon of patients with IBD who began treatment with vedolizumab (n [ 31) or tumor necrosis factor (TNF) antagonists (n [ 20) and performed RNA-sequencing analyses. We compared gene expression patterns between patients who did and did not enter endoscopic remission (absence of ulcerations at month 6 for patients with Crohn's disease or Mayo endoscopic subscore £1 at week 14 for patients with ulcerative colitis) and performed pathway analysis and cell deconvolution for training (n [ 20) and validation (n [ 11) datasets. Colon biopsies were also analyzed by immunohistochemistry. We validated a baseline gene expression pattern associated with endoscopic remission after vedolizumab therapy using 3 independent datasets (n [ 66). RESULTS: We identified significant differences in expression levels of 44 genes between patients who entered remission after vedolizumab and those who did not; we found significant increases in leukocyte migration in colon tissues from patients who did not enter remission (P < .006). Deconvolution methods identified a significant enrichment of monocytes (P [ .005), M1macrophages (P [ .05), and CD4D T cells (P [ .008) in colon tissues from patients who did not enter remission, whereas colon tissues from patients in remission had higher numbers of naïve B cells before treatment (P [ .05). Baseline expression levels of PIWIL1, MAATS1, RGS13, and DCHS2 identified patients who did vs did not enter remission with 80% accuracy in the training set and 100% accuracy in validation dataset 1. We validated these findings in the 3 independent datasets by microarray, RNA sequencing and quantitative PCR analysis (P [ .003). Expression levels of these 4 genes did not associate with response to anti-TNF agents. We confirmed the presence of proteins encoded by mRNAs using immunohistochemistry. CONCLUSIONS: We identified 4 genes whose baseline expression levels in colon tissues of patients with IBD associate with endoscopic remission after vedolizumab, but not anti-TNF, treatment. We validated this signature in 4 independent datasets and also at the protein level. Studies of these genes might provide insights into the mechanisms of action of vedolizumab.

Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

“…We believe further studies will help us decipher key predictors of response within the identified direct mechanisms of action that, in a manner similar to predictors, should be unique to each specific drug type. 54 …”

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study

“…While several potential biomarkers have been reported [19][20][21], such approaches require further validations before entering clinical practice. To the contrary, clinical characteristics of patients are easy to collect and may directly help to estimate outcomes.…”

Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapy

“…Furthermore, in UC patients non-responsive to anti-α4β7 treatment, we observed reduced M2 macrophage levels. Verstockt et al transcriptomic analysis of UC tissue from patients prior to receiving biologic therapy revealed significant enrichment of immune cells in non-responders including M1 macrophages and Tregs, while responders had elevated naïve B cells 65 . Our CIBERSORT analysis also showed a trend in elevated M1 macrophages, while changes in Tregs were insignificant.…”